My understanding to date is, Novavax completed Phase 0-IV clinical trials, unlike some other candidates, before applying for EAU/licensing and despite substantial barriers to distribution created by MIC authorities. Novavax Inc COVID-19 vaccine availability and nominal coverage is  comparatively limited by design. It obtained license for Nuvaxvid in EU on or about 21 Dec 2021 after licensing production of Covashield and Covovax brand names in India, mid 3Q2021. By then, Israel R(0) data had damaged "market leader" Pfizer mRNA reputation. Still have no clue what Novavax coverage is in S America.

eurotrib archive Novavax

Hep B, Hep A, Hep C, Hib, HPV, etc.
I'm not aware of any Hep B:MS incidence correlations. AFAIK, I've never taken that vaccine or tested pos, as child or adult. As indicated previously, I'm more disturbed by general incoherence in basic research and clinical treatment of MS symptoms.

I for one don't have objections to  conventional, conjugate "tech" and am not "anti-vax". Granted, I've had no reason based on adverse vaccine experiences to be suspicious. But I have discriminated (as adult and for my child) between FDA warnings, purported beneficial use, and statutory schedules. So I read both Pfizer, Moderna, J&J FDA applications before EUAs and was distinctly unimpressed by Pfizer's trial design [cockroach alert]. As The state limited J&J availability--even at "mass vaccination" sites--I deliberately ignored HHS eligibility "guidance," waited 5 mo until 2nd choice (Moderna) was offered by appointment at my primary care office. Extended family members (age 16-53) represent combinations of mRNA + J&J dosages, Feb 2021-Jan2022. 9 mo later--specifically because of "passport" hysteria gripping westworld--I decided to take a Moderna "booster", simply to update compliance bona fides. But I've no intention to do so again, as probability of multi-dose vaccine injury is not well understood and I truly do not want to complicate MS prognosis.